Restructuring On The Table For FibroGen After Roxadustat Rejection

 
• By Alaric DeArment
Malekidneys-cancer
The FDA issued a complete response letter for FibroGen and AstraZeneca's roxadustat in anemia of chronic kidney disease • Source: Shutterstock

More from Strategy

More from Business